knowledge -WSS

knowledge

author：comprehensive 2025-10-03 01:06:13 - browse：33

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Dairy farmers resist CDC push for PPE against bird flu virus

WSS

Health AI: on the border between health care and tech

Biden administration begins canceling student loan debt for 804,000 borrowers

Illumina slashes 2023 revenue projections yet again

Google says AlphaFold 3 can map a vast universe of biomolecules

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Steward Health Care files for bankruptcy

leisure time

knowledge

entertainment

How to save PrEP access — and even expand it

Bird flu researchers hone in on Finland’s mink farms

In Memoriam: Notable people who died in 2023

Illinois Supreme Court finds assault weapons ban constitutional

Apple is now the first public company to be valued at $3 trillion

Indictment alleges Trump's ex

What does generative AI mean for health care? We asked experts

Treatments for cramps don't cut it. Why aren't there better options?

United colonoscopy coverage change 'may cost lives,' doctors say

Aspartame and sugar

entertainment

Judge sides with young activists in first

Biogen’s boardroom scandal saddles CEO with first crisis

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

YouTube cracks down on misinformation on cancer treatment

Study: Adult vaccinations pay for themselves in societal benefits

After Optum profits sink, UnitedHealth makes changes

leisure time

focus

focus

hotspot